Research progress in the use of mesenchymal stem cells to inhibit intimal hyperplasia in arteriovenous fistula in uremic patients

LUO Tong; YAN Yan

doi:10.3969/j.issn.1671-4091.2025.03.012

2025 , Vol. 24 >Issue 03: 226 - 230

DOI: https://doi.org/10.3969/j.issn.1671-4091.2025.03.012

Research progress in the use of mesenchymal stem cells to inhibit intimal hyperplasia in arteriovenous fistula in uremic patients

LUO Tong ,
YAN Yan

Expand

Department of Nephrology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China

Received date: 2024-09-19

Revised date: 2024-12-16

Online published: 2025-03-12

Supported by

Fold

Abstract

The incidence of chronic kidney disease (CKD) is increasing year by year. Continuous progress of CKD may finally lead to end-stage renal disease (ESRD). Maintenance hemodialysis (MHD) is one of the alternative treatments for ESRD patients, and arteriovenous fistula (AVF) is the preferred type of blood access for MHD. However, AVF dysfunction occurs frequently, leading to a short lifetime of blood access. Narrowing of AVF by neointimal hyperplasia is the main cause of AVF dysfunction. Previous studies have shown that both systemic and local treatments may inhibit the intimal hyperplasia. Mesenchymal stem cells have the potentials of diverse differentiation, self-renewal, tissue repair, homing and paracrine activities, probably useful for the reversal of neointimal hyperplasia in AVF. This article reviews recent advances in the mechanism and treatment of AVF dysfunction, the use of mesenchymal stem cells, and the mechanisms underlying the reversal of neointimal hyperplasia, in order to find out new ideas for the prevention of AVF dysfunction.

Key words： Mesenchymal stem cell; Uremia; Maintenance hemodialysis; Arteriovenous fistula; Intimal hyperplasia

Cite this article

LUO Tong , YAN Yan . Research progress in the use of mesenchymal stem cells to inhibit intimal hyperplasia in arteriovenous fistula in uremic patients[J]. Chinese Journal of Blood Purification, 2025 , 24(03) : 226 -230 . DOI: 10.3969/j.issn.1671-4091.2025.03.012

References

[1] 朱思懿, 洪航, 边学燕, 等. 慢性肾脏病流行病学研究进展. 预防医学. 2023;35(09):770-3.
[2] Mitrofanova A, Merscher S, Fornoni A. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. Nat Rev Nephrol. 2023;19(10):629-45.
[3] Grassmann A, Gioberge S, Moeller S, etal. End-stage renal disease: global demographics in 2005 and observed trends. Artif Organs. 2006;30(12):895-7.
[4] Gupta R, Woo K, Yi JA. Epidemiology of end-stage kidney disease. Semin Vasc Surg. 2021;34(1):71-8.
[5] Vazquez-Padron RI, Duque JC, Tabbara M, etal. Intimal Hyperplasia and Arteriovenous Fistula Failure: Looking Beyond Size Differences. Kidney360. 2021;2(8):1360-72.
[6] Ma S, Duan S, Liu Y, etal. Intimal Hyperplasia of Arteriovenous Fistula. Ann Vasc Surg. 2022;85:444-53.
[7] Jalaeefar A, Mohammadi Tofigh A, Gharib A, etal. Effects of N-acetylcysteine on arterial neo-intimal hyperplasia in rat model of arteriovenous fistula. J Vasc Access. 2019;20(2):190-4.
[8] Jeon JW, Kim HR, Lee E, etal. Effect of cilostazol on arteriovenous fistula in hemodialysis patients. Nefrologia (Engl Ed). 2021.
[9] Tabbara M, Duque JC, Martinez L, etal. Pre-existing and Postoperative Intimal Hyperplasia and Arteriovenous Fistula Outcomes. Am J Kidney Dis. 2016;68(3):455-64.
[10] Somarathna M, Hwang PT, Millican RC, etal. Nitric oxide releasing nanomatrix gel treatment inhibits venous intimal hyperplasia and improves vascular remodeling in a rodent arteriovenous fistula. Biomaterials. 2022;280:121254.
[11] Lan T, Luo M, Wei X. Mesenchymal stem/stromal cells in cancer therapy. J Hematol Oncol. 2021;14(1):195.
[12] Liu J, Gao J, Liang Z, etal. Mesenchymal stem cells and their microenvironment. Stem Cell Res Ther. 2022;13(1):429.
[13] Ding DC, Chang YH, Shyu WC, etal. Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant. 2015;24(3):339-47.
[14] Hu C, Li L. Preconditioning influences mesenchymal stem cell properties in?vitro and in?vivo. J Cell Mol Med. 2018;22(3):1428-42.
[15] Gong W, Wang F, He Y, etal. Mesenchymal Stem Cell Therapy for Oral Inflammatory Diseases: Research Progress and Future Perspectives. Curr Stem Cell Res Ther. 2021;16(2):165-74.
[16] Chen F, Chen N, Xia C, etal. Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges. Cell Transplant. 2023;32:9636897231164251.
[17] Kouroupis D, Sanjurjo-Rodriguez C, Jones E, etal. Mesenchymal Stem Cell Functionalization for Enhanced Therapeutic Applications. Tissue Eng Part B Rev. 2019;25(1):55-77.
[18] Bagno L, Hatzistergos KE, Balkan W, etal. Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges. Mol Ther. 2018;26(7):1610-23.
[19] Wang LT, Liu KJ, Sytwu HK, etal. Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells. Stem Cells Transl Med. 2021;10(9):1288-303.
[20] Mishra VK, Shih HH, Parveen F, etal. Identifying the Therapeutic Significance of Mesenchymal Stem Cells. Cells. 2020;9(5).
[21] Zhao G, Ge Y, Zhang C, etal. Progress of Mesenchymal Stem Cell-Derived Exosomes in Tissue Repair. Curr Pharm Des. 2020;26(17):2022-37.
[22] Yue WM, Liu W, Bi YW, etal. Mesenchymal stem cells differentiate into an endothelial phenotype, reduce neointimal formation, and enhance endothelial function in a rat vein grafting model. Stem Cells Dev. 2008;17(4):785-93.
[23] Sun P, Wu H, Bai X, etal. Decellularized fish swim bladder patch loaded with mesenchymal stem cells inhibits neointimal hyperplasia. J Biomed Mater Res B Appl Biomater. 2023;111(3):551-9.
[24] 束波, 范芳. 基质细胞衍生因子1(SDF-1)预处理的骨髓间充质干细胞移植减轻大鼠颈动脉内皮和平滑肌细胞增生. 细胞与分子免疫学杂志. 2019;35(04):320-6.
[25] Kim AK, Kim MH, Kim DH, etal. Inhibitory effects of mesenchymal stem cells in intimal hyperplasia after balloon angioplasty. J Vasc Surg. 2016;63(2):510-7.
[26] Zou X, Liao Y, Liu Z, etal. Exosomes Derived from AT2R-Overexpressing BMSC Prevent Restenosis After Carotid Artery Injury by Attenuating the Injury-Induced Neointimal Hyperplasia. J Cardiovasc Transl Res. 2023;16(1):112-26.
[27] Wang D, Gao B, Yue J, etal. Exosomes from mesenchymal stem cells expressing miR-125b inhibit neointimal hyperplasia via myosin IE. J Cell Mol Med. 2019;23(2):1528-40.
[28] Homma J, Sekine H, Matsuura K, etal. Mesenchymal Stem Cell Sheets Exert Antistenotic Effects in a Rat Arterial Injury Model. Tissue Eng Part A. 2018;24(19-20):1545-53.
[29] Piryani AK, Kilari S, Takahashi E, etal. Rationale and Trial Design of MesEnchymal Stem Cell Trial in Preventing Venous Stenosis of Hemodialysis Vascular Access Arteriovenous Fistula (MEST AVF Trial). Kidney360. 2021;2(12):1945-52.
[30] Cai C, Kilari S, Zhao C, etal. Therapeutic Effect of Adipose Derived Mesenchymal Stem Cell Transplantation in Reducing Restenosis in a Murine Angioplasty Model. J Am Soc Nephrol. 2020;31(8):1781-95.
[31] Yang B, Brahmbhatt A, Nieves Torres E, etal. Tracking and Therapeutic Value of Human Adipose Tissue-derived Mesenchymal Stem Cell Transplantation in Reducing Venous Neointimal Hyperplasia Associated with Arteriovenous Fistula. Radiology. 2016;279(2):513-22.
[32] Barcena AJR, Perez JVD, Bernardino MR, etal. Bioresorbable Mesenchymal Stem Cell-Loaded Electrospun Polymeric Scaffold Inhibits Neointimal Hyperplasia Following Arteriovenous Fistula Formation in a Rat Model of Chronic Kidney Disease. Adv Healthc Mater. 2023;12(26):e2300960.

Options

Outlines

模态框（Modal）标题

Abstract

Cite this article

References